Macular Hole Progression after Intravitreal Bevacizumab for Hemicentral Retinal Vein Occlusion by Nagpal, Manish et al.
Hindawi Publishing Corporation
Case Reports in Ophthalmological Medicine
Volume 2011, Article ID 679751, 3 pages
doi:10.1155/2011/679751
Case Report
Macular Hole Progression after Intravitreal Bevacizumab for
HemicentralRetinal VeinOcclusion
ManishNagpal, VikramMehta,and Kamal Nagpal
Department of Vitreo Retina, Retina Foundation, Shahibag, Gujarat, Ahmedabad 380004, India
Correspondence should be addressed to Manish Nagpal, drmanishnagpal@yahoo.com
Received 9 November 2011; Accepted 28 December 2011
Academic Editor: D. K. Roberts
Copyright © 2011 Manish Nagpal et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Macular edema secondary to retinal vein occlusion is commonly being treated with oﬀ-label intravitreal bevacizumab with good
outcomes. A signiﬁcant reduction in macular edema and improvement in visual acuity is seen following such a treatment with no
serious adverse eﬀects. In the reported case, a full-thickness macular hole was noticed one month after intravitreal bevacizumab
for macular edema secondary to hemicentral retinal vein occlusion. On a detailed review of the pre- and postoptical coherence
tomography scans, it was realized that there was a preexisting stage 2-3 macular hole which was masked by the hemorrhages and
edema at the fovea and the macular hole had progressed following the injection.
1.Introduction
Intravitreal injection of bevacizumab appears to result in
signiﬁcant short-term improvement of visual acuity and
macular edema secondary to retinal venous occlusion [1].
Bevacizumab has been reported to be well tolerated with
negligible ocular toxicity or adverse eﬀects [2].
We report our unusual experience while treating a case of
hemicentral retinal vein occlusion with macular edema.
2.CaseReport
A 60-years-old lady presented to us with complaints of
decreased vision in the left eye for 2 months. Best corrected
visual acuity was 20/60 in the right eye and 3/60 in the
left eye with normal intraocular pressure. Anterior segment
examination was unremarkable except for a grade 2 nuclear
sclerosis in both eyes. Fundus examination of the left
eye revealed a superior hemicentral retinal vein occlusion
(HCRVO), which was documented on ﬂuorescein angiog-
raphy as well (Figures 1(a) and 1(b)). Optical coherence
tomography (OCT) revealed cystoid edema with loss of
normal foveal contour (Figure 1(c)). Fundus evaluation of
the right eye was normal. She was treated with intravitreal
injection of bevacizumab (1.25mg) after a detailed discus-
sion and informed consent explaining the risks involved
and the oﬀ-label use. At one-month followup, there was
no subjective or objective improvement in vision. Fundus
examination revealed reduction in the retinal hemorrhages
and a full-thickness macular hole which was evident on OCT
as well (Figures 2(a) and 2(b)). Retrospectively, analyzing the
preinjection OCT, it was realized that the irregular foveal
margins were because of a preexisting stage 2-3 macular hole
camouﬂaged by the hemorrhages and edema at the fovea
which had progressed following the injection.
3. Discussion
Lamellar macular holes and rarely full-thickness macular
holesareoccasionalcomplicationsofchronicmacularedema
in venous occlusions [3]. The macular hole in this case
was seen in the early phase of the occlusion, and, hence, it
was probably an HCRVO developing in a case of idiopathic
macular hole. However, the possibility of macular edema
initiating an early macular hole cannot be completely ruled
out.
The intravitreal bevacizumab injection could have prob-
ably led to the progression of the macular hole. There
have been isolated reports of formation/progression of
macular hole following intravitreal triamcinolone for central
retinal vein occlusion [4, 5]. Changes in the structure





Figure 1: (a) Fundus photograph of the left eye showing superﬁcial
retinal hemorrhages, cotton wool spots, and tortuous and dilated
retinal veins in the superior half of the retina involving the
macula.TheseﬁndingswereconsistentwithasuperiorHCRVO.(b)
Fluorescein angiography demonstrated blocked ﬂuorescence due
to retinal hemorrhages with areas of capillary non perfusion. (c)
Vertical 5mm OCT scan along the arrow shows cystoid edema with
retinal hemorrhages in the superior half of the fovea (right half of
the scan) and some retinal discontinuity which in retrospect was a
stage 2-3 macular hole. Hyaloidal attachment is also seen.
are known. Possible peripheral vitreous pull exerted by a
minimal vitreous incarceration at the injection site could
account for anteroposterior traction [4]. Numerous reports
have already shown that intravitreal bevacizumab induces a
promptimprovementinmacularedemasecondarytovenous
occlusions as observed in our patient [1, 2]. The shrinkage of
macular thickness combined with anteroposterior traction





Figure 2: (a) Fundus photograph, one month after intravitreal
bevacizumab injection, showing decreased haemorrhages with a
full-thickness macular hole. (b) Vertical 5mm OCT scan along the
same line shows progression to a full-thickness macular hole with
a detached hyaloid and a pseudooperculum causing a shadowing
behind it.
In summary, combined HCRVO with idiopathic macular
hole is a rare presentation. Diagnosis of macular hole could
be diﬃcult in such a scenario, and OCT is a useful tool
for its detection. Commonly practiced treatment of macular
edema for venous occlusion such as oﬀ label intravitreal
bevacizumab could cause a progression of the macular
hole, and, hence, careful examination of the macular OCT
image should include careful scrutiny for early macular hole
formation. Overall prognosis despite resolution of macular
edema will be guarded due to the presence and progression
of the macular hole.
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